Show simple item record

dc.contributor.authorKemp M.M.
dc.contributor.authorLinhardt, Robert J.
dc.date2010
dc.date.accessioned2022-06-27T16:10:54Z
dc.date.available2022-06-27T16:10:54Z
dc.date.issued2010
dc.identifier.citationHeparin-based nanoparticles, M. M. Kemp and R. J. Linhardt, Nanomedicine and Nanobiotechnology, 2, 77 – 87, 2010.
dc.identifier.urihttps://doi.org/10.1002/wnan.68
dc.identifier.urihttps://hdl.handle.net/20.500.13015/5743
dc.descriptionNanomedicine and Nanobiotechnology, 2, 77–87
dc.descriptionNote : if this item contains full text it may be a preprint, author manuscript, or a Gold OA copy that permits redistribution with a license such as CC BY. The final version is available through the publisher’s platform.
dc.description.abstractNumerous papers on heparin nanoparticles have been reported regarding targeting therapy and biomedical imaging. Here, we have summarized the prospects and opportunities of heparin as a carrier for cancer targeting and imaging. First, we proposed heparin-anticancer drug conjugates showing higher anticancer activity than free drug. The conjugated heparin (heparin-deoxycholate sodium) retained its ability to bind with angiogenic factors, showing a significant decrease in endothelial tubular formation. Second, targeting ligands conjugated heparin derivatives have introduced for a receptor mediated delivery of anticancer drug. Heparin-folic acid-retinoic acid (HFR) bioconjugates for treating cancer cells showed 3 fold higher efficacy than heparin-retinoic acid (HR). Besides active and passive targeting drug delivery, several papers have been reported regarding delivery of imaging agents by heparin nanoparticles. Finally, this research highlight has covered imaging agents such as gold nanoparticles and quantum dots (QDs) for noninvasive biomedical imaging. Very recently our group demonstrated that semiconductor QDs loaded heparin nanoparticles could also be administered through orally for noninvasive imaging. Due to promising features of heparin such as less toxic polysaccharide and easier modification, it was considered as a potent carrier for imaging agent and drug delivery.
dc.description.urihttps://login.libproxy.rpi.edu/login?url=https://doi.org/10.1002/wnan.68
dc.languageen_US
dc.language.isoENG
dc.relation.ispartofThe Linhardt Research Labs Online Collection
dc.relation.ispartofRensselaer Polytechnic Institute, Troy, NY
dc.relation.urihttps://harc.rpi.edu/
dc.subjectBiology
dc.subjectChemistry and chemical biology
dc.subjectChemical and biological engineering
dc.subjectBiomedical engineering
dc.titleHeparin-based nanoparticles
dc.typeArticle
dcterms.accessRightshttps://login.libproxy.rpi.edu/login?url=https://doi.org/10.1002/wnan.68
dcterms.isVersionOfhttps://doi.org/10.1002/wnan.68
dc.rights.holderIn Copyright : this Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s). https://rightsstatements.org/page/InC/1.0/
dc.creator.identifierhttps://orcid.org/0000-0003-2219-5833
dc.relation.departmentThe Linhardt Research Labs.
dc.relation.departmentThe Shirley Ann Jackson, Ph.D. Center for Biotechnology and Interdisciplinary Studies (CBIS)


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record